NCT04897802View on ClinicalTrials.gov

Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)

PHASE4RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

April 30, 2024

Study Completion Date

December 31, 2024

Conditions
HypopituitarismCentral Diabetes InsipidusPanhypopituitarismPsychological DisorderSocial IsolationHypothalamic DiseasesPituitary DiseasesOxytocin Deficiency
Interventions
DRUG

Experimental: GLP1-RA (exenatide) administration

a single dose of 10 mcg of GLP-RA (exenatide) will be administered subcutaneously and samples to assess OT secretory patterns will be collected over 2 hours

DRUG

Control: Placebo administration

Sodium Chloride 0.9% will be administered subcutaneously at equivalent volume than 10 mcg of exenatide

Trial Locations (1)

08041

RECRUITING

Hospital de la Santa Creu i Sant Pau, Barcelona

All Listed Sponsors
collaborator

Instituto de Salud Carlos III

OTHER_GOV

lead

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER